ALX Oncology Narrows Q2 Loss, Extends Cash Runway to First Half of 2028, and Sets Mid-2027 Evorpacept Readout

summarizeSummary

ALX Oncology reported a narrower Q2 net loss of $17.97M ($0.13/share) and ended with $153.4M in cash, providing runway through the first half of 2028. The company reaffirmed mid-2027 topline data for its lead program evorpacept and expects initial safety data for ALX2004 later this year.

check_boxKey Events · Earnings and Guidance · ALXO

• Q2 Loss Narrows to $17.97M

  Net loss of $17.97M ($0.13/share) vs. $25.9M ($0.49/share) a year ago, driven by a $4.9M drop in R&D expenses and lower G&A costs.

• Cash Runway Through 1H 2028

  Cash, equivalents, and investments totaled $153.4M at June 30, 2026, which management believes is sufficient to fund operations through the first half of 2028.

• Evorpacept Phase 2 Data Mid-2027

  Topline data from 80 patients in the ASPEN-09-Breast trial of evorpacept in HER2-positive metastatic breast cancer is expected in mid-2027.

• ALX2004 Safety Data 2H 2026

  Initial safety data from the Phase 1 dose-escalation trial of ALX2004, an EGFR-targeted ADC, is on track for the second half of 2026.

auto_awesomeAnalysis · ALXO · Life Sciences

A sharply narrower Q2 net loss of $17.97M ($0.13/share), down from $25.9M a year ago, underscores ALX Oncology's tighter cost control, with R&D and G&A expenses both declining. The company ended the quarter with $153.4M in cash, which it says funds operations through the first half of 2028 — a critical survival signal for a clinical-stage biotech. Concrete catalysts now line the path ahead: topline data from the Phase 2 ASPEN-09-Breast trial of lead candidate evorpacept is expected in mid-2027, and initial safety data for ALX2004, an EGFR-targeted ADC, is due in the second half of 2026. These milestones, combined with a strengthened balance sheet after a recent debt refinancing, give investors a clearer route to value-creating events.